Tag - AXGT

Developments

Axovant gets FDA rare pediatric designation for gangliosidosis gene therapy

Axovant Gene Therapies (NASDAQ:AXGT) received FDA orphan drug designation for AXO-AAV-GM1 for the treatment of GM1 gangliosidosis. GM1 gangliosidosis is a progressive and fatal disease where mutations in the GLB1 gene...

October 9, 2020

Developments

Axovant gets FDA orphan drug designation for gangliosidosis gene therapy

Axovant Gene Therapies (NASDAQ:AXGT) received FDA orphan drug designation for AXO-AAV-GM1 for the treatment of GM1 gangliosidosis. GM1 gangliosidosis is a rare genetic disease where mutations in the GLB1 gene impair...

November 18, 2019

Developments

Axovant reports six-month data from Phase 2 Parkinson’s disease trial

Axovant Gene Therapies (NASDAQ:AXGT) reported six-month data from its Phase 2 trial of AXO-Lenti-PD, a gene therapy for Parkinson’s disease (PD). AXO-Lenti-PD uses a single lentiviral vector to deliver three genes...

June 6, 2019

Developments

Axovant doses first patient in gangliosidosis gene therapy trial

Axovant Gene Therapies (NASDAQ:AXGT) has dosed the first patient in a clinical study of AXO-AAV-GM1 for the treatment of GM1 gangliosidosis. GM1 gangliosidosis is a rare genetic disease where mutations in the GLB1 gene...

May 17, 2019

Tag - AXGT

Axovant gets FDA rare pediatric designation for gangliosidosis gene therapy

Axovant gets FDA orphan drug designation for gangliosidosis gene therapy

Axovant reports six-month data from Phase 2 Parkinson’s disease trial

Axovant doses first patient in gangliosidosis gene therapy trial

General

More